Systemic delivery of umbilical cord blood cells for stroke therapy

A review

Guolong Yu, Cesar V. Borlongan, Christine E. Stahl, David C Hess, Yali Ou, Yuji Kaneko, Seong Jin Yu, Tianlun Yang, Li Fang, Xiumei Xie

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Purpose: This review paper summarizes relevant studies, discusses potential mechanisms of transplanted cell-mediated neuroprotection, and builds a case for the need to establish outcome parameters that are critical for transplantation success. In particular, we outline the advantages and disadvantages of systemic delivery of human umbilical cord blood (HUCB) cells in the field of cellular transplantation for treating ischemic stroke. Methods: A MEDLINE/PubMed systematic search of published articles in peer-reviewed journals over the last 25 years was performed focusing on the theme of HUCB as donor graft source for transplantation therapy in neurological disorders with emphasis on stroke. Results: Ischemic stroke remains a leading cause of human death and disability. Although stroke survivors may gain spontaneous partial functional recovery, they often suffer from sensory-motor dysfunction, behavioral/neurological alterations, and various degrees of paralysis. Currently, limited clinical intervention is available to prevent ischemic damage and restore lost function in stroke victims. Stem cells from fetal tissues, bone marrow, and HUCB has emerged in the last few years as a potential cell transplant cell source for ischemic stroke, because of their capability to differentiate into multiple cell types and the possibility that they may provide trophic support for cell survival, tissue repair, and functional recovery. Conclusion: A growing number of studies highlight the potential of systemic delivery of HUCB cells as a novel therapeutic approach for stroke. However, additional preclinical studies are warranted to reveal the optimal HUCB transplant regimen that is safe and efficacious prior to proceeding to large-scale clinical application of these cells for stroke therapy.

Original languageEnglish (US)
Pages (from-to)41-54
Number of pages14
JournalRestorative Neurology and Neuroscience
Volume27
Issue number1
DOIs
StatePublished - Feb 20 2009

Fingerprint

Cell- and Tissue-Based Therapy
Fetal Blood
Blood Cells
Stroke
Transplantation
Transplants
Nervous System Diseases
Blood Donors
PubMed
MEDLINE
Paralysis
Survivors
Cause of Death
Cell Survival
Fetus
Stem Cells
Bone Marrow
Therapeutics

Keywords

  • Adult stem cells
  • Cerebral ischemia
  • Neuroprotection
  • Neurorestoration
  • Transplantation

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Systemic delivery of umbilical cord blood cells for stroke therapy : A review. / Yu, Guolong; Borlongan, Cesar V.; Stahl, Christine E.; Hess, David C; Ou, Yali; Kaneko, Yuji; Yu, Seong Jin; Yang, Tianlun; Fang, Li; Xie, Xiumei.

In: Restorative Neurology and Neuroscience, Vol. 27, No. 1, 20.02.2009, p. 41-54.

Research output: Contribution to journalReview article

Yu, G, Borlongan, CV, Stahl, CE, Hess, DC, Ou, Y, Kaneko, Y, Yu, SJ, Yang, T, Fang, L & Xie, X 2009, 'Systemic delivery of umbilical cord blood cells for stroke therapy: A review', Restorative Neurology and Neuroscience, vol. 27, no. 1, pp. 41-54. https://doi.org/10.3233/RNN-2009-0460
Yu, Guolong ; Borlongan, Cesar V. ; Stahl, Christine E. ; Hess, David C ; Ou, Yali ; Kaneko, Yuji ; Yu, Seong Jin ; Yang, Tianlun ; Fang, Li ; Xie, Xiumei. / Systemic delivery of umbilical cord blood cells for stroke therapy : A review. In: Restorative Neurology and Neuroscience. 2009 ; Vol. 27, No. 1. pp. 41-54.
@article{1a43783b78cc4812a418636309fe9383,
title = "Systemic delivery of umbilical cord blood cells for stroke therapy: A review",
abstract = "Purpose: This review paper summarizes relevant studies, discusses potential mechanisms of transplanted cell-mediated neuroprotection, and builds a case for the need to establish outcome parameters that are critical for transplantation success. In particular, we outline the advantages and disadvantages of systemic delivery of human umbilical cord blood (HUCB) cells in the field of cellular transplantation for treating ischemic stroke. Methods: A MEDLINE/PubMed systematic search of published articles in peer-reviewed journals over the last 25 years was performed focusing on the theme of HUCB as donor graft source for transplantation therapy in neurological disorders with emphasis on stroke. Results: Ischemic stroke remains a leading cause of human death and disability. Although stroke survivors may gain spontaneous partial functional recovery, they often suffer from sensory-motor dysfunction, behavioral/neurological alterations, and various degrees of paralysis. Currently, limited clinical intervention is available to prevent ischemic damage and restore lost function in stroke victims. Stem cells from fetal tissues, bone marrow, and HUCB has emerged in the last few years as a potential cell transplant cell source for ischemic stroke, because of their capability to differentiate into multiple cell types and the possibility that they may provide trophic support for cell survival, tissue repair, and functional recovery. Conclusion: A growing number of studies highlight the potential of systemic delivery of HUCB cells as a novel therapeutic approach for stroke. However, additional preclinical studies are warranted to reveal the optimal HUCB transplant regimen that is safe and efficacious prior to proceeding to large-scale clinical application of these cells for stroke therapy.",
keywords = "Adult stem cells, Cerebral ischemia, Neuroprotection, Neurorestoration, Transplantation",
author = "Guolong Yu and Borlongan, {Cesar V.} and Stahl, {Christine E.} and Hess, {David C} and Yali Ou and Yuji Kaneko and Yu, {Seong Jin} and Tianlun Yang and Li Fang and Xiumei Xie",
year = "2009",
month = "2",
day = "20",
doi = "10.3233/RNN-2009-0460",
language = "English (US)",
volume = "27",
pages = "41--54",
journal = "Restorative Neurology and Neuroscience",
issn = "0922-6028",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Systemic delivery of umbilical cord blood cells for stroke therapy

T2 - A review

AU - Yu, Guolong

AU - Borlongan, Cesar V.

AU - Stahl, Christine E.

AU - Hess, David C

AU - Ou, Yali

AU - Kaneko, Yuji

AU - Yu, Seong Jin

AU - Yang, Tianlun

AU - Fang, Li

AU - Xie, Xiumei

PY - 2009/2/20

Y1 - 2009/2/20

N2 - Purpose: This review paper summarizes relevant studies, discusses potential mechanisms of transplanted cell-mediated neuroprotection, and builds a case for the need to establish outcome parameters that are critical for transplantation success. In particular, we outline the advantages and disadvantages of systemic delivery of human umbilical cord blood (HUCB) cells in the field of cellular transplantation for treating ischemic stroke. Methods: A MEDLINE/PubMed systematic search of published articles in peer-reviewed journals over the last 25 years was performed focusing on the theme of HUCB as donor graft source for transplantation therapy in neurological disorders with emphasis on stroke. Results: Ischemic stroke remains a leading cause of human death and disability. Although stroke survivors may gain spontaneous partial functional recovery, they often suffer from sensory-motor dysfunction, behavioral/neurological alterations, and various degrees of paralysis. Currently, limited clinical intervention is available to prevent ischemic damage and restore lost function in stroke victims. Stem cells from fetal tissues, bone marrow, and HUCB has emerged in the last few years as a potential cell transplant cell source for ischemic stroke, because of their capability to differentiate into multiple cell types and the possibility that they may provide trophic support for cell survival, tissue repair, and functional recovery. Conclusion: A growing number of studies highlight the potential of systemic delivery of HUCB cells as a novel therapeutic approach for stroke. However, additional preclinical studies are warranted to reveal the optimal HUCB transplant regimen that is safe and efficacious prior to proceeding to large-scale clinical application of these cells for stroke therapy.

AB - Purpose: This review paper summarizes relevant studies, discusses potential mechanisms of transplanted cell-mediated neuroprotection, and builds a case for the need to establish outcome parameters that are critical for transplantation success. In particular, we outline the advantages and disadvantages of systemic delivery of human umbilical cord blood (HUCB) cells in the field of cellular transplantation for treating ischemic stroke. Methods: A MEDLINE/PubMed systematic search of published articles in peer-reviewed journals over the last 25 years was performed focusing on the theme of HUCB as donor graft source for transplantation therapy in neurological disorders with emphasis on stroke. Results: Ischemic stroke remains a leading cause of human death and disability. Although stroke survivors may gain spontaneous partial functional recovery, they often suffer from sensory-motor dysfunction, behavioral/neurological alterations, and various degrees of paralysis. Currently, limited clinical intervention is available to prevent ischemic damage and restore lost function in stroke victims. Stem cells from fetal tissues, bone marrow, and HUCB has emerged in the last few years as a potential cell transplant cell source for ischemic stroke, because of their capability to differentiate into multiple cell types and the possibility that they may provide trophic support for cell survival, tissue repair, and functional recovery. Conclusion: A growing number of studies highlight the potential of systemic delivery of HUCB cells as a novel therapeutic approach for stroke. However, additional preclinical studies are warranted to reveal the optimal HUCB transplant regimen that is safe and efficacious prior to proceeding to large-scale clinical application of these cells for stroke therapy.

KW - Adult stem cells

KW - Cerebral ischemia

KW - Neuroprotection

KW - Neurorestoration

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=60249083368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249083368&partnerID=8YFLogxK

U2 - 10.3233/RNN-2009-0460

DO - 10.3233/RNN-2009-0460

M3 - Review article

VL - 27

SP - 41

EP - 54

JO - Restorative Neurology and Neuroscience

JF - Restorative Neurology and Neuroscience

SN - 0922-6028

IS - 1

ER -